Pfizer, Ex­act Sciences to co-mar­ket col­orec­tal cancer di­ag­nos­tic test

BioSpectrum (India) - - WORLD NEWS -

Molec­u­lar di­ag­nos­tics com­pany Ex­act Sciences and Pfizer have signed a multi-year agree­ment to co-mar­ket the Co­lo­guard test for di­ag­nos­ing col­orec­tal cancer in the US. Co­lo­guard is one of the only US Food and Drug Ad­min­is­tra­tion (FDA) ap­proved and non-in­va­sive stool DNA screen­ing di­ag­nos­tics for cancer.By pro­mot­ing the test, Ex­act Sciences and Pfizer in­tend to boost col­orec­tal cancer screen­ing rates. Ex­act Science’s sales force, the science of Co­lo­guard and a di­rect-to-con­sumer mar­ket­ing cam­paign will be com­bined with Pfizer’s health sys­tems net­work and mar­ket­ing ex­per­tise. Ex­act Sciences will con­tinue to carry out all man­u­fac­tur­ing and lab­o­ra­tory op­er­a­tions of the test. Pfizer will evenly share gross prof­its and mar­ket­ing costs above an agreed base­line.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.